---
title: "Neuphoria Therapeutics rises on $15 mln milestone payment from Merck"
date: "2025-02-12 23:50:11"
summary: "** Massachusetts-based drug developer Neuphoria Therapeutics rises 3.31% to $4.65 in morning trade ** Co, which develops treatments for brain and mental health disorders, says it is due to receive $15 million milestone payment from Merck ** The payment is triggered by the start of a mid-stage study for the..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Massachusetts-based drug developer Neuphoria Therapeutics rises 3.31% to $4.65 in morning trade

\*\* Co, which develops treatments for brain and mental health disorders, [says](https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nGNX9z7GXR&default-theme=true) it is due to receive $15 million milestone payment from Merck

\*\* The payment is triggered by the start of a mid-stage study for the treatment of Merck's Alzheimer's disease dementia

\*\* The study is estimated to complete on July 20,Â 2027

\*\* The study is to test if the experimental drug, MK-1167, given along with another therapy that affects memory, which can improve symptoms of Alzheimer's disease dementia such as memory and mental activity

\*\* NEUP is eligible to receive up to $450 million in additional milestone payments if certain developments are achieved

\*\* In the last 12 months, the stock down 70%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31CW:0-neuphoria-therapeutics-rises-on-15-mln-milestone-payment-from-merck/)
